Last reviewed · How we verify
Placebo matching with Dapagliflozin
Placebo matching with Dapagliflozin is a SGLT2 inhibitor Small molecule drug developed by AstraZeneca. It is currently in Phase 3 development for Type 2 diabetes mellitus, Heart failure with reduced ejection fraction, Chronic kidney disease.
Dapagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to increase urinary glucose excretion and lower blood glucose levels.
Dapagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to increase urinary glucose excretion and lower blood glucose levels. Used for Type 2 diabetes mellitus, Heart failure with reduced ejection fraction, Chronic kidney disease.
At a glance
| Generic name | Placebo matching with Dapagliflozin |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 (sodium-glucose cotransporter 2) |
| Modality | Small molecule |
| Therapeutic area | Diabetes, Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Dapagliflozin blocks SGLT2, a transporter protein in the proximal tubule of the kidney that normally reabsorbs filtered glucose back into the bloodstream. By inhibiting this transporter, the drug allows excess glucose to be excreted in the urine, thereby reducing blood glucose concentrations. This mechanism is independent of insulin secretion or action, making it effective across different diabetes phenotypes.
Approved indications
- Type 2 diabetes mellitus
- Heart failure with reduced ejection fraction
- Chronic kidney disease
Common side effects
- Genital mycotic infections
- Urinary tract infections
- Polyuria
- Hypotension
- Diabetic ketoacidosis
Key clinical trials
- A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure (PHASE3)
- Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function (PHASE3)
- A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. (PHASE2)
- Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin (PHASE3)
- Dapagliflozin in Active Lupus Nephritis (PHASE4)
- A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure. (PHASE3)
- A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK (PHASE2)
- The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo matching with Dapagliflozin CI brief — competitive landscape report
- Placebo matching with Dapagliflozin updates RSS · CI watch RSS
- AstraZeneca portfolio CI
Frequently asked questions about Placebo matching with Dapagliflozin
What is Placebo matching with Dapagliflozin?
How does Placebo matching with Dapagliflozin work?
What is Placebo matching with Dapagliflozin used for?
Who makes Placebo matching with Dapagliflozin?
What drug class is Placebo matching with Dapagliflozin in?
What development phase is Placebo matching with Dapagliflozin in?
What are the side effects of Placebo matching with Dapagliflozin?
What does Placebo matching with Dapagliflozin target?
Related
- Drug class: All SGLT2 inhibitor drugs
- Target: All drugs targeting SGLT2 (sodium-glucose cotransporter 2)
- Manufacturer: AstraZeneca — full pipeline
- Therapeutic area: All drugs in Diabetes, Cardiovascular
- Indication: Drugs for Type 2 diabetes mellitus
- Indication: Drugs for Heart failure with reduced ejection fraction
- Indication: Drugs for Chronic kidney disease
- Compare: Placebo matching with Dapagliflozin vs similar drugs
- Pricing: Placebo matching with Dapagliflozin cost, discount & access